Aurora BioScience is the regional partner for Sanuwave Health’s new and exciting wound treatment technology. Sanuwave Health is an emerging leader in the development and commercialisation of noninvasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures.
Sanuwave’s primary market segment is wound care and dermaPACE is our lead product that addresses diabetic foot ulcers along with decubitus (pressure ulcers), burns and chronic wounds.
The dermaPACE device has received TGA approval for the treatment of acute and chronic defects of the skin and subcutaneous soft tissues e.g. post-operative wound healing defects, post-traumatic wounds, deep partial thickness burns, decubitus ulcers, diabetic ulcers, and arterial ulcers. Given that current conservative therapy or standard of care may not be effective for all patients, PACE may be a preferable, lower risk alternative.